Aliases & Classifications for Colitis

MalaCards integrated aliases for Colitis:

Name: Colitis 12 77 30 56 6 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:0060180
MeSH 45 D003092
NCIt 51 C26723
SNOMED-CT 69 64226004
ICD10 34 K52.9
UMLS 74 C0009319

Summaries for Colitis

Disease Ontology : 12 An inflammatory bowel disease that involves inflammation located in colon.

MalaCards based summary : Colitis is related to crohn's colitis and crohn's disease. An important gene associated with Colitis is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs tannic acid and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include colon, t cells and neutrophil, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 77 Colitis is an inflammation of the colon. Colitis may be acute and self-limited or long-term. It broadly... more...

Related Diseases for Colitis

Diseases related to Colitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1115)
# Related Disease Score Top Affiliating Genes
1 crohn's colitis 33.9 CXCL8 IFNG IL1B IL2 NOD2 TNF
2 crohn's disease 33.0 ABCB1 ATG16L1 IL10 IL10RA IL10RB IL23R
3 pyoderma gangrenosum 32.9 CXCL8 NOD2 TNF
4 ulcerative colitis 32.9 ABCB1 ATG16L1 CTNNB1 CXCL8 IFNG IL10
5 pouchitis 32.8 CXCL8 IL10 NOD2
6 inflammatory bowel disease 25, autosomal recessive 32.8 IL10 IL10RA IL10RB
7 gastroenteritis 32.7 CXCL8 IL10 IL1B IL6 TNF
8 dengue shock syndrome 31.8 IL1B IL6 TNF
9 ileocolitis 31.8 MYO9B NOD2 TNF
10 ileitis 31.7 IL17A IL6 MPO NOD2 TNF
11 pyoderma 31.6 CXCL8 NOD2 TNF
12 cytomegalovirus infection 30.9 CXCL8 IL1B IL6 TNF
13 spondyloarthropathy 1 30.8 IL17A NOD2 TNF
14 inflammatory bowel disease 30.6 ABCB1 ATG16L1 CXCL8 IFNG IL10 IL10RA
15 familial mediterranean fever 30.6 IL1B NOD2 TNF
16 esophagitis 30.6 CXCL8 IL1B IL6
17 aspergillosis 30.5 IFNG IL10 TNF
18 acute pancreatitis 30.5 CXCL8 IL10 IL6 MPO
19 appendicitis 30.5 CXCL8 IL10 IL1B IL6 MPO TNF
20 pneumonia 30.5 CXCL8 IL10 IL1B IL6 MPO TNF
21 spinal cord injury 30.5 CXCL8 IL6 TNF
22 cystitis 30.5 CXCL8 IL6 TNF
23 erythema multiforme 30.4 IFNG IL2 TNF
24 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 IFNG IL10 IL17A
25 herpes zoster 30.4 IFNG IL10 IL2
26 alopecia areata 30.4 IFNG IL2 TNF
27 fasciitis 30.4 CXCL8 IL6 TNF
28 pericarditis 30.4 IFNG IL1B IL6 TNF
29 hidradenitis 30.4 IL17A NOD2 TNF
30 kawasaki disease 30.4 IL10 IL6 TNF
31 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 30.4 IFNG IL10 IL2
32 spondylitis 30.3 IL17A IL23R IL6 NOD2 TNF
33 peritonitis 30.3 CXCL8 IL10 IL1B IL6 MPO TNF
34 hidradenitis suppurativa 30.3 IL17A NOD2 TNF
35 acquired immunodeficiency syndrome 30.3 IFNG IL10 IL1B IL2 IL6 TNF
36 inflammatory bowel disease 5 30.2 ATG16L1 IL23R NOD2
37 arthritis 30.2 CXCL8 IFNG IL10 IL17A IL1B IL6
38 neuritis 30.2 IFNG IL1B TNF
39 aplastic anemia 30.2 IFNG IL2 IL6 TNF
40 acute generalized exanthematous pustulosis 30.2 CXCL8 IL17A
41 wells syndrome 30.2 CXCL8 IL1B IL2
42 hematopoietic stem cell transplantation 30.2 IFNG IL10 IL2 IL6 TNF
43 autoimmune inner ear disease 30.2 MPO TNF
44 reactive arthritis 30.2 IFNG IL10 IL17A TNF
45 endomyocardial fibrosis 30.1 IL10 TNF
46 hepatitis a 30.1 IFNG IL10 TNF
47 obstructive jaundice 30.1 CXCL8 IL6 TNF
48 graft-versus-host disease 30.1 IFNG IL10 IL1B IL2 IL6 TNF
49 necrotizing fasciitis 30.1 CXCL8 IL2 IL6
50 uveitis 30.1 IFNG IL10 IL17A NOD2 TNF

Graphical network of the top 20 diseases related to Colitis:



Diseases related to Colitis

Symptoms & Phenotypes for Colitis

GenomeRNAi Phenotypes related to Colitis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.88 CXCL8 IL10 IL17A IL1B IL2 MPO
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.88 CXCL8 IL10 IL17A IL1B IL2 MPO

MGI Mouse Phenotypes related to Colitis:

47 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
2 digestive/alimentary MP:0005381 10.37 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
3 homeostasis/metabolism MP:0005376 10.36 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
4 immune system MP:0005387 10.36 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RA
5 growth/size/body region MP:0005378 10.34 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
6 cellular MP:0005384 10.33 ATG16L1 CTNNB1 IFNG IL10 IL10RA IL10RB
7 cardiovascular system MP:0005385 10.3 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL1B
8 endocrine/exocrine gland MP:0005379 10.29 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
9 mortality/aging MP:0010768 10.21 ABCB1 ATG16L1 CTNNB1 IFNG IL10 IL10RB
10 craniofacial MP:0005382 10.08 CTNNB1 IFNG IL10 IL17A IL1B SMAD4
11 liver/biliary system MP:0005370 10.06 ABCB1 CTNNB1 IFNG IL10 IL10RB IL2
12 muscle MP:0005369 9.92 ATG16L1 CTNNB1 IFNG IL10 IL6 MPO
13 neoplasm MP:0002006 9.91 CTNNB1 IFNG IL10 IL1B IL2 IL23R
14 no phenotypic analysis MP:0003012 9.76 ABCB1 CTNNB1 IFNG IL10 IL17A IL2
15 respiratory system MP:0005388 9.56 CTNNB1 IFNG IL10 IL10RB IL17A IL2
16 skeleton MP:0005390 9.28 CTNNB1 IFNG IL10 IL17A IL1B IL6

Drugs & Therapeutics for Colitis

Drugs for Colitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 504)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
3
Hydrocortisone Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-23-7 5754
4
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 50-03-3
5
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
6
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 170277-31-3
7
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
8
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
9
Copper Approved, Investigational Phase 4 7440-50-8 27099
10
Tocopherol Approved, Investigational Phase 4,Phase 2,Not Applicable 1406-66-2 14986
11
leucovorin Approved Phase 4,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
12
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 32051
13 Vedolizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 943609-66-3
14
Mercaptopurine Approved Phase 4,Phase 3,Phase 2,Not Applicable 50-44-2 667490
15
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 302-25-0
16
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2921-57-5
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 50-24-8 5755
18
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83-43-2 6741
19
Sodium Citrate Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 68-04-2
20
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65-49-6 4649
21
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 93-14-1 3516
22
Vancomycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1404-90-6 14969 441141
23
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2 428863-50-7
24
Loperamide Approved Phase 4,Phase 3,Phase 2,Not Applicable 53179-11-6 3955
25
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
26
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 53-03-2 5865
27
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
28
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 6473866 445643 439492
29
Linaclotide Approved Phase 4 851199-59-2 65351
30
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 80621-81-4 46783403 6436173
31
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
32
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
33
Cefazolin Approved Phase 4,Phase 3,Phase 2,Not Applicable 25953-19-9 33255 656510
34
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
35
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
36
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 443-48-1 4173
37
Nicotine Approved Phase 4,Not Applicable 54-11-5 89594 942
38
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Not Applicable 564-25-0 54671203
39
Tofacitinib Approved, Investigational Phase 4,Phase 3,Phase 1 477600-75-2
40
carbamide peroxide Approved Phase 4 124-43-6
41
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
42
Trimethoprim Approved, Vet_approved Phase 4,Not Applicable 738-70-5 5578
43
Sulfamethoxazole Approved Phase 4,Not Applicable 723-46-6 5329
44
Methotrexate Approved Phase 4,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
45
Ustekinumab Approved, Investigational Phase 4,Phase 3 815610-63-0
46
Magnesium citrate Approved Phase 4 3344-18-1
47
Losartan Approved Phase 4 114798-26-4 3961
48
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
49
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
50
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696

Interventional clinical trials:

(show top 50) (show all 1382)
# Name Status NCT ID Phase Drugs
1 Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis Unknown status NCT02962245 Phase 4 berberine;regular treatment
2 Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission Unknown status NCT02412085 Phase 4 Golimumab
3 Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab Unknown status NCT02186886 Phase 4 Golimumab
4 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4 Probiotic
5 Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe Unknown status NCT01630096 Phase 4 Nu-Lytely
6 Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis Unknown status NCT03110198 Phase 4 Mesalazine;hydrocortisone sodium succinate;Mesalazine with hydrocortisone sodium succinate
7 Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing Unknown status NCT02998112 Phase 4 fecal microbiota transplantation;Saline
8 Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis Unknown status NCT02579733 Phase 4 Azathioprine;Placebo
9 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4 Infliximab-Biosimilar;Infliximab-Innovator
10 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
11 Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD Unknown status NCT03059849 Phase 4 Adalimumab
12 Anemia in Inflammatory Bowel Disease Unknown status NCT02760940 Phase 4 oral liposomal iron
13 Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab Unknown status NCT02453776 Phase 4 PRECISION dosing Infliximab
14 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease Unknown status NCT01632462 Phase 4 VSL#3
15 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4 Probiotic;Placebo
16 Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
17 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
18 Pain Relief In Irritable Bowel Syndrome Unknown status NCT02573844 Phase 4 Proklama
19 Duration of Antibiotic Therapy in Community - Acquired Pneumonia Unknown status NCT01492387 Phase 4
20 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
21 Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) Completed NCT02092285 Phase 4 Golimumab
22 Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle Completed NCT01772615 Phase 4 Ciprofloxacin
23 Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis Completed NCT01408810 Phase 4 Infliximab
24 Predicting Response to Standardized Pediatric Colitis Therapy Completed NCT01536535 Phase 4 Mesalamine;Corticosteroid;Corticosteroids then mesalamine
25 Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) Completed NCT02155335 Phase 4 Prefilled Syringe delivery of Golimumab;Smartject Device delivery of Golimumab
26 Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) Completed NCT00446849 Phase 4 MMX Mesalamine
27 Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis Completed NCT01201122 Phase 4 Mesalamine
28 Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). Completed NCT02318667 Phase 4
29 Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis Completed NCT00542152 Phase 4 CYCLOSPORINE VS INFLIXIMAB
30 Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease Completed NCT02559713 Phase 4 Vedolizumab
31 Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis Completed NCT01124149 Phase 4 MMX mesalamine/ mesalazine
32 Asacol Dosing Study for Active Ulcerative Colitis Completed NCT00194818 Phase 4 Asacol (mesalamine)
33 Adacolumn in Refractory UC Patients Trial Completed NCT01481142 Phase 4
34 Dose Escalation and Remission (DEAR) Completed NCT00652145 Phase 4 mesalamine
35 Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) Completed NCT00219414 Phase 4
36 The NOR-SWITCH Study Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
37 Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis Completed NCT01418131 Phase 4 Rectal tacrolimus;Placebo
38 Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) Completed NCT01346826 Phase 4 Standard 2 hours-infusion;Accelerated 1 hour-infusion;Accelerated 30 minutes-infusion
39 Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate Completed NCT01991314 Phase 4 Ferrous sulphate
40 Low Volume Colon Preparation for IBD Completed NCT02248337 Phase 4 Colon preparation for colonoscopy
41 Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease Completed NCT01908283 Phase 4
42 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
43 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
44 The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels Completed NCT00167882 Phase 4 5-aminosalicylate (Pentasa, Ferring)
45 Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients Completed NCT01341808 Phase 4
46 Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease Completed NCT01981889 Phase 4 Prednisone
47 Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea Completed NCT01670149 Phase 4 Rifaximin;Placebo
48 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4 23-valent polysaccharide pneumococcal vaccine
49 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
50 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4

Search NIH Clinical Center for Colitis

Cochrane evidence based reviews: colitis

Genetic Tests for Colitis

Genetic tests related to Colitis:

# Genetic test Affiliating Genes
1 Colitis 30

Anatomical Context for Colitis

MalaCards organs/tissues related to Colitis:

42
Colon, T Cells, Neutrophil, Liver, Bone, Lung, Testes

The Foundational Model of Anatomy Ontology organs/tissues related to Colitis:

20
Colon

Publications for Colitis

Articles related to Colitis:

(show top 50) (show all 11951)
# Title Authors Year
1
Fecal microbiota transplantation for severe complicated C. difficile colitis in a patient with acquired immunodeficiency syndrome. ( 29449093 )
2019
2
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission-confounded by the gut microbiome? ( 30920041 )
2019
3
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920043 )
2019
4
Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply. ( 30920048 )
2019
5
Persistent Central Inflammation and Region Specific Cellular Activation Accompany Depression- and Anxiety-like Behaviours During the Resolution Phase of Experimental Colitis. ( 31063848 )
2019
6
The Preventive and Curative Effects of Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 on Immobilization Stress-Induced Anxiety/Depression and Colitis in Mice. ( 30979031 )
2019
7
Electroacupuncture and Moxibustion Improved Anxiety Behavior in DSS-Induced Colitis Mice. ( 30881446 )
2019
8
Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase. ( 30735453 )
2019
9
Identification of New Potential Therapies for Colitis Amelioration Using an Appendicitis-Appendectomy Model. ( 30329049 )
2019
10
Bowel-associated dermatosis arthritis syndrome and palisading neutrophilic granulomatous dermatitis as presentation of ulcerative colitis. ( 30924626 )
2019
11
Leflunomide-induced colitis in association with enterocutaneous fistula in an immunosuppressed patient with renal transplant and rheumatoid arthritis. ( 30820830 )
2019
12
Chronic colitis induces meninges traffic of gut-derived T cells, unbalances M1 and M2 microglia/macrophage and increases ischemic brain injury in mice. ( 30445026 )
2019
13
Sequelae of breast pyoderma gangrenosum associated with ulcerative colitis: Impact on breast cancer screening. ( 31077481 )
2019
14
Infliximab-induced bullous pemphigoid and anti-desmoglein 3 and anti-BP180 autoantibodies in a patient with ulcerative colitis. ( 30530408 )
2019
15
The recruitment of extra-intestinal cells to the injured mucosa promotes healing in radiation enteritis and chemical colitis in a mouse parabiosis model. ( 30617302 )
2019
16
Fluid supplementation accelerates epithelial repair during chemical colitis. ( 31002683 )
2019
17
Oral Vancomycin Induces and Maintains Remission of Ulcerative Colitis in the Subset of Patients With Associated Primary Sclerosing Cholangitis. ( 30838381 )
2019
18
Sarcoidosis of the Intra- and Extrahepatic Bile Ducts with Concomitant Cholangitis in a Patient with Ulcerative Colitis. ( 31097931 )
2019
19
High Serum sCD40 and a Distinct Colonic T Cell Profile in Ulcerative Colitis Associated With Primary Sclerosing Cholangitis. ( 30383225 )
2019
20
A Prospective Program to Reduce the Clinical Incidence of Clostridium difficile Colitis Infection after Cystectomy. ( 30218764 )
2019
21
Fidaxomicin and Fecal Microbiota Transplants for Severe Clostridium difficile Colitis. ( 30601771 )
2019
22
Trends in Incidence and Outcomes of Clostridium difficile Colitis in Hospitalized Patients of Febrile Neutropenia: A Nationwide Analysis. ( 30614941 )
2019
23
Nonsteroidal Anti-inflammatory Drugs Alter the Microbiota and Exacerbate Clostridium difficile Colitis while Dysregulating the Inflammatory Response. ( 30622186 )
2019
24
Clostridium difficile Colitis Prevention and Treatment. ( 30689174 )
2019
25
Prolonged non-operative management of clostridium difficile colitis is associated with increased mortality, complications, and cost. ( 30709552 )
2019
26
Clostridium difficile colitis in patients undergoing surgery for hip fractures: an analysis of 17,474 patients. ( 30799640 )
2019
27
Development of a Standardized Scoring System to Assess a Murine Model of Clostridium difficile Colitis. ( 30892111 )
2019
28
Thrombin generation is increased in patients with Clostridium difficile colitis - a pilot study. ( 30907672 )
2019
29
Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control Clostridium difficile colitis. ( 30948494 )
2019
30
Enterotoxigenic Clostridium perfringens Infection as an Adverse Event After Faecal Microbiota Transplantation in Two Patients With Ulcerative Colitis and Recurrent Clostridium difficile Infection: A Neglected Agent in Donor Screening. ( 30852608 )
2019
31
Endoscopy in Postoperative Patients with Crohn's Disease or Ulcerative Colitis. Does It Translate to Better Outcomes? ( 31078249 )
2019
32
Strictures in Crohn's Disease and Ulcerative Colitis: Is There a Role for the Gastroenterologist or Do We Always Need a Surgeon? ( 31078252 )
2019
33
Pharmacological mechanism of Sishen Wan® attenuated experimental chronic colitis by inhibiting wnt/β-catenin pathway. ( 31078692 )
2019
34
Low-Dose Interleukin-2 Ameliorates Colitis in a Preclinical Humanized Mouse Model. ( 31078723 )
2019
35
A Unique Presentation of Infantile-Onset Colitis and Eosinophilic Disease without Recurrent Infections Resulting from a Novel Homozygous CARMIL2 Variant. ( 31079270 )
2019
36
Recurrent Inflammatory Myositis as an Extra-Intestinal Manifestation of Dormant Ulcerative Colitis in a Patient on Long-Term Mesalamine. ( 31080678 )
2019
37
A rare case of bullous Sweet's Syndrome in a patient with inactive ulcerative colitis. ( 31081562 )
2019
38
Melatonin alleviates circadian rhythm disruption exacerbating DSS-induced colitis by inhibiting the distribution of HMGB1 in intestinal tissues. ( 31082723 )
2019
39
Correction: Dietary Gluten Intake and Risk of Microscopic Colitis Among US Women Without Celiac Disease: A Prospective Cohort Study. ( 31082842 )
2019
40
Small bowel capsule endoscopy in ulcerative colitis: the capcolitis study: a prospective observational study. ( 31082999 )
2019
41
Clinical significance of signs of autoimmune colitis in 18F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients. ( 31088239 )
2019
42
Gangrenous ischaemic colitis following lung wedge resection. ( 31088812 )
2019
43
Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey. ( 31090656 )
2019
44
Microscopic colitis: Struggling with an invisible, disabling disease. ( 31090966 )
2019
45
Platelet Depletion/Transfusion as a Lethal Factor in a Colitis-associated Cancer Mouse Model. ( 31092437 )
2019
46
Huangkui Lianchang Decoction Ameliorates DSS-Induced Ulcerative Colitis in Mice by Inhibiting the NF-kappaB Signaling Pathway. ( 31093294 )
2019
47
Dose-response relationship between cigarette smoking and risk of ulcerative colitis: a nationwide population-based study. ( 31093771 )
2019
48
Acute Severe Ulcerative Colitis: The Oxford Criteria No Longer Predict In-Hospital Colectomy Rates. ( 31093812 )
2019
49
The Writing Is on the Wall: The Utility of Mural Stratification for Risk Stratification of Hospitalized Patients with Severe Ulcerative Colitis. ( 31093813 )
2019
50
Celiac disease associated with ulcerative colitis. ( 31094177 )
2019

Variations for Colitis

ClinVar genetic disease variations for Colitis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
2 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869
3 FLNA NM_001456.3(FLNA): c.7439C> A (p.Thr2480Asn) single nucleotide variant Uncertain significance rs909387820 GRCh38 Chromosome X, 154349738: 154349738
4 FLNA NM_001456.3(FLNA): c.7439C> A (p.Thr2480Asn) single nucleotide variant Uncertain significance rs909387820 GRCh37 Chromosome X, 153578106: 153578106
5 CIITA NM_000246.3(CIITA): c.3344G> A (p.Ser1115Asn) single nucleotide variant Uncertain significance GRCh37 Chromosome 16, 11017111: 11017111
6 CIITA NM_000246.3(CIITA): c.3344G> A (p.Ser1115Asn) single nucleotide variant Uncertain significance GRCh38 Chromosome 16, 10923254: 10923254

Expression for Colitis

Search GEO for disease gene expression data for Colitis.

Pathways for Colitis

Pathways related to Colitis according to GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.13 CTNNB1 CXCL8 IFNG IL10 IL10RA IL10RB
2
Show member pathways
13.97 CTNNB1 CXCL8 IL10 IL10RA IL10RB IL17A
3
Show member pathways
13.79 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
4
Show member pathways
13.66 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
5
Show member pathways
13.54 CXCL8 IL10 IL10RA IL10RB IL17A IL1B
6
Show member pathways
13.46 CXCL8 IFNG IL10 IL10RA IL10RB IL17A
7
Show member pathways
13.34 CTNNB1 CXCL8 IL10 IL10RA IL10RB IL17A
8
Show member pathways
13.24 ATG16L1 CXCL8 IFNG IL10 IL1B IL2
9
Show member pathways
13.09 CTNNB1 CXCL8 IL10RA IL10RB IL1B IL6
10 12.97 CTNNB1 CXCL8 IFNG IL2 IL23R IL6
11
Show member pathways
12.82 CXCL8 IFNG IL1B IL6 TNF
12
Show member pathways
12.77 ABCB1 CXCL8 IFNG IL10 IL10RA IL10RB
13
Show member pathways
12.76 IFNG IL10 IL10RA IL10RB IL2 TNF
14
Show member pathways
12.73 IFNG IL10 IL17A IL1B IL2 IL6
15 12.72 IFNG IL10 IL17A IL1B IL2 MPO
16
Show member pathways
12.56 IFNG IL10 IL10RA IL10RB IL2 IL23R
17
Show member pathways
12.49 IFNG IL1B IL2 IL6 MPO TNF
18
Show member pathways
12.49 CXCL8 IFNG IL17A IL1B IL6 TNF
19 12.47 CTNNB1 IL2 IL6 SMAD4 TNF
20
Show member pathways
12.43 CXCL8 IFNG IL1B IL6 TNF
21
Show member pathways
12.43 CXCL8 IFNG IL10 IL17A IL1B IL2
22
Show member pathways
12.43 IFNG IL10 IL10RA IL10RB IL1B IRGM
23
Show member pathways
12.43 IFNG IL10 IL10RB IL17A IL1B IL2
24 12.37 IFNG IL10 IL10RA IL10RB IL1B IL6
25
Show member pathways
12.35 IL10 IL1B IL2 IL6 TNF
26 12.35 CTNNB1 CXCL8 IL10 IL1B IL6 TNF
27
Show member pathways
12.33 CXCL8 IFNG IL1B IL6 TNF
28